×

Use of semaphorin-4D binding molecules for treating neurodegenerative disorders

  • US 10,385,136 B2
  • Filed: 03/21/2017
  • Issued: 08/20/2019
  • Est. Priority Date: 10/21/2013
  • Status: Active Grant
First Claim
Patent Images

1. A method of treating a subject having a having, determined to have, or suspected of having a neuroinflammatory or neurodegenerative disorder, comprising administering to the subject an effective amount of an isolated antibody or antigen-binding fragment thereof that specifically binds to SEMA4D, wherein the antibody or antigen-binding fragment thereof comprises a variable heavy chain (VH) comprising VHCDRs 1-3 comprising SEQ ID NOs 6, 7, and 8, respectively, and a variable light chain (VL) comprising VLCDRs 1-3 comprising SEQ ID NOs 14, 15, and 16, respectively, and wherein the binding to SEMA4D acts to alleviate symptoms associated with the disorder.

View all claims
  • 3 Assignments
Timeline View
Assignment View
    ×
    ×